Publications

Santi, D.V. et al. Macromolecular Prodrug That Provides the Irinotecan (CPT-11) Active-Metabolite SN-38 with Ultralong Half-Life, Low Cmax, and Low Glucuronide Formation. J. Med. Chem. 57: 2303-2314. (2014)

Fontaine, S.D. et al. Species-Specific Optimization of PEG-SN-38 Prodrug Pharmacokinetics and Antitumor Effects in a Triple-Negative BRCA1-Deficient Xenograft. Cancer Chemother. Pharmacol. 84: 729-738. (2019)

Fontaine, S.D. et al. PLX038: A PEGylated Prodrug of SN-38 Independent of UGT1A1 Activity. Cancer Chemother. Pharmacol. 85: 225-229. (2020)

Beckford Vera, D.R. et al. PET Imaging of the EPR Effect in Tumor Xenografts Using Small 15 nm Diameter Polyethylene Glycols Labeled with Zirconium-89. Mol. Cancer Ther. 19: 673-679. (2020)

Ghilu, S. et al. Prospective Use of the Single-Mouse Experimental Design for the Evaluation of PLX038A. Cancer Chemother. Pharmacol. 85: 251-263. (2020)

Santi, D.V. et al. Does Sacituzumab-Govitecan Act as a Conventional Antibody Drug Conjugate (ADC), a Prodrug of SN-38 or Both?. Ann. Transl. Med. 9: 1113. (2021)

Thomas, A. et al. PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors. Mol. Cancer Ther. 21: 1722-1728. (2022)

Santi, D.V. et al. Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?. BioDrugs 38: 171-176. (2024)

Henise, J. et al. A Platform Technology for Ultra-Long Acting Intratumoral Therapy. Sci. Rep. 14: 14000. (2024)

Jung, J. et al. PLX038A, a Long-Acting SN-38, Penetrates the Blood-Tumor-Brain-Barrier, Accumulates and Releases SN-38 in Brain Tumors to Increase Survival of Tumor Bearing Mice. Sci. Rep. 14: 14175. (2024)

Meher, N. et al. PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer. Mol. Cancer Ther. 24: 141-151. (2025)

Hou, X. et al. Antitumor Activity of Rucaparib Plus PLX038A in Serous Endometrial Carcinoma. J. Exp. Clin. Cancer Res. 44: 150. (2025)

Angelis Oncology. ⁸⁹Zr-starPEG as a PET Imaging Surrogate for Drug-Loaded Conjugates: A Retrospective Analysis in Glioblastoma and Other Tumor Models. Preprint in preparation. (2026)